Skip to content

Study · Non-randomized trial · n = 5 · 2006

9 results

Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome.

Akintoye SO, Kelly MH, Brillante B, Cherman N, Turner S, Butman JA, Robey PG, Collins MT

The Journal of clinical endocrinology and metabolism23 May 2006Cited by 36 (Europe PMC)

PMID16720661 (opens in a new tab)DOI10.1210/jc.2005-2661 (opens in a new tab)PepBankPUB-16720661
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In MAS patients with GH excess, pegvisomant reduced serum IGF-I at 6 weeks by 236.4 ng/ml (53%, P < 0.005).

    In plain wordsIn MAS patients with excess GH, pegvisomant reduced IGF-I at 6 weeks compared with baseline.

    Peptide
    Pegvisomant
    Outcome
    DecreaseIGF-I change at 6 weeks
    Study

    n = 5

    Analysis
    Primary
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 mg/d · subcutaneousAs given in this study (human).

    Measurements

    IGF-I change
    −236.4 ng/ml
    6 weeks
    IGF-I reduction
    53%
    6 weeks

    Source sentences

    Summary
    Combined mean changes in serum IGF-I at 6 and 12 wk were -236.4 ng/ml (53%, P < 0.005) and -329.8 ng/ml (62%, P < 0.001), respectively.
    1 context sentence
    Summary · context
    Five MAS patients with GH excess were treated with 20 mg/d sc injection of pegvisomant for 12 wk in a randomized, double-blind, placebo-controlled crossover study at the National Institutes of Health.
  2. 02HumanNon-randomized trialEfficacy outcome

    In MAS patients with GH excess, pegvisomant reduced serum IGF-I at 12 weeks by 329.8 ng/ml (62%, P < 0.001).

    In plain wordsIn MAS patients with excess GH, pegvisomant reduced IGF-I at 12 weeks compared with baseline.

    Peptide
    Pegvisomant
    Outcome
    DecreaseIGF-I change at 12 weeks
    Study

    n = 5

    Analysis
    Primary
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 mg/d · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    IGF-I change
    −329.8 ng/ml
    12 weeks
    IGF-I reduction
    62%
    12 weeks

    Source sentences

    Summary
    Combined mean changes in serum IGF-I at 6 and 12 wk were -236.4 ng/ml (53%, P < 0.005) and -329.8 ng/ml (62%, P < 0.001), respectively.
    1 context sentence
    Summary · context
    Five MAS patients with GH excess were treated with 20 mg/d sc injection of pegvisomant for 12 wk in a randomized, double-blind, placebo-controlled crossover study at the National Institutes of Health.
  3. 03HumanNon-randomized trialEfficacy outcome

    In MAS patients with GH excess, pegvisomant reduced IGFBP-3 at 6 weeks by 0.8 mg/liter (24%, P < 0.01).

    In plain wordsIn MAS patients with excess GH, pegvisomant reduced IGFBP-3 at 6 weeks compared with baseline.

    Peptide
    Pegvisomant
    Outcome
    DecreaseIGFBP-3 change at 6 weeks
    Study

    n = 5

    Analysis
    Secondary
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 mg/d · subcutaneousAs given in this study (human).

    Measurements

    IGFBP-3 decrease
    0.8 mg/liter
    6 weeks
    IGFBP-3 reduction
    24%
    6 weeks

    Source sentences

    Summary
    IGFBP-3 decreased by 0.8 mg/liter (24%, P < 0.01) and 2.9 mg/liter (37%, P < 0.005), respectively.
    2 context sentences
    Summary · context
    Combined mean changes in serum IGF-I at 6 and 12 wk were -236.4 ng/ml (53%, P < 0.005) and -329.8 ng/ml (62%, P < 0.001), respectively.
    Summary · context
    Five MAS patients with GH excess were treated with 20 mg/d sc injection of pegvisomant for 12 wk in a randomized, double-blind, placebo-controlled crossover study at the National Institutes of Health.
  4. 04HumanNon-randomized trialEfficacy outcome

    In MAS patients with GH excess, pegvisomant reduced IGFBP-3 at 12 weeks by 2.9 mg/liter (37%, P < 0.005).

    In plain wordsIn MAS patients with excess GH, pegvisomant reduced IGFBP-3 at 12 weeks compared with baseline.

    Peptide
    Pegvisomant
    Outcome
    DecreaseIGFBP-3 change at 12 weeks
    Study

    n = 5

    Analysis
    Secondary
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 mg/d · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    IGFBP-3 decrease
    2.9 mg/liter
    12 weeks
    IGFBP-3 reduction
    37%
    12 weeks

    Source sentences

    Summary
    IGFBP-3 decreased by 0.8 mg/liter (24%, P < 0.01) and 2.9 mg/liter (37%, P < 0.005), respectively.
    2 context sentences
    Summary · context
    Combined mean changes in serum IGF-I at 6 and 12 wk were -236.4 ng/ml (53%, P < 0.005) and -329.8 ng/ml (62%, P < 0.001), respectively.
    Summary · context
    Five MAS patients with GH excess were treated with 20 mg/d sc injection of pegvisomant for 12 wk in a randomized, double-blind, placebo-controlled crossover study at the National Institutes of Health.
  5. 05HumanNon-randomized trialEfficacy outcome

    In MAS patients with GH excess, pegvisomant did not significantly change signs and symptoms of acromegaly.

    In plain wordsIn MAS patients with excess GH, pegvisomant did not significantly change acromegaly signs or symptoms from baseline.

    Peptide
    Pegvisomant
    Outcome
    No significant changeAcromegaly signs and symptoms
    Study

    n = 5

    Analysis
    Secondary
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 mg/d · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    There were no significant changes in signs and symptoms of acromegaly or markers of bone metabolism and bone pain, nor was there a significant change in pituitary size.
    1 context sentence
    Summary · context
    Five MAS patients with GH excess were treated with 20 mg/d sc injection of pegvisomant for 12 wk in a randomized, double-blind, placebo-controlled crossover study at the National Institutes of Health.
  6. 06HumanNon-randomized trialEfficacy outcome

    In MAS patients with GH excess, pegvisomant did not significantly change markers of bone metabolism.

    In plain wordsIn MAS patients with excess GH, pegvisomant did not significantly change bone metabolism markers from baseline.

    Peptide
    Pegvisomant
    Outcome
    No significant changeBone metabolism markers
    Study

    n = 5

    Analysis
    Secondary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 mg/d · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    There were no significant changes in signs and symptoms of acromegaly or markers of bone metabolism and bone pain, nor was there a significant change in pituitary size.
    1 context sentence
    Summary · context
    Five MAS patients with GH excess were treated with 20 mg/d sc injection of pegvisomant for 12 wk in a randomized, double-blind, placebo-controlled crossover study at the National Institutes of Health.
  7. 07HumanNon-randomized trialEfficacy outcome

    In MAS patients with GH excess, pegvisomant did not significantly change bone pain.

    In plain wordsIn MAS patients with excess GH, pegvisomant did not significantly change bone pain from baseline.

    Peptide
    Pegvisomant
    Outcome
    No significant changeBone pain
    Study

    n = 5

    Analysis
    Secondary
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    20 mg/d · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    There were no significant changes in signs and symptoms of acromegaly or markers of bone metabolism and bone pain, nor was there a significant change in pituitary size.
    1 context sentence
    Summary · context
    Five MAS patients with GH excess were treated with 20 mg/d sc injection of pegvisomant for 12 wk in a randomized, double-blind, placebo-controlled crossover study at the National Institutes of Health.
  8. 08HumanNon-randomized trialEfficacy outcome

    In MAS patients with GH excess, pegvisomant did not significantly change pituitary size.

    In plain wordsIn MAS patients with excess GH, pegvisomant did not significantly change pituitary size from baseline.

    Peptide
    Pegvisomant
    Outcome
    No significant changePituitary size
    Study

    n = 5

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 mg/d · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    There were no significant changes in signs and symptoms of acromegaly or markers of bone metabolism and bone pain, nor was there a significant change in pituitary size.
    1 context sentence
    Summary · context
    Five MAS patients with GH excess were treated with 20 mg/d sc injection of pegvisomant for 12 wk in a randomized, double-blind, placebo-controlled crossover study at the National Institutes of Health.
  9. 09HumanObservational studyEfficacy outcome

    In MAS patients with GH excess, retrospective comparison linked pegvisomant to similar disease control as long-acting octreotide with or without dopamine agonist.

    In plain wordsIn MAS patients, retrospective comparison linked pegvisomant to similar control as long-acting octreotide with or without dopamine agonist.

    Peptide
    Pegvisomant
    Outcome
    No significant changeDisease control versus previous medication
    Study

    n = 5

    Comparator
    Long-acting octreotide with or without dopamine agonist
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 mg/d · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Retrospective comparison of the degree of control achieved with pegvisomant vs. other medications (long-acting octreotide +/- dopamine agonist) in the same group showed that the two regimens were similarly effective.
    1 context sentence
    Summary · context
    Five MAS patients with GH excess were treated with 20 mg/d sc injection of pegvisomant for 12 wk in a randomized, double-blind, placebo-controlled crossover study at the National Institutes of Health.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.